Ovarian Cancer Drug Olaparib Extends ...

Ovarian Cancer Drug Olaparib Extends Progression Free Survival

There are 1 comment on the MediLexicon story from May 19, 2011, titled Ovarian Cancer Drug Olaparib Extends Progression Free Survival. In it, MediLexicon reports that:

A Phase II trial showed that Olaparib significantly extends progression-free survival of participants with SOC who had completed chemotherapy.

Join the discussion below, or Read more at MediLexicon.

Since: Dec 05

Reading, PA

#1 May 23, 2011
Can PARP Inhibitors be tested with the Functional Profiling Platform?

Functional analysis of PARP inhibitors Olaparib (AZD-2281) and Iniparib (BSI-201) in human tumor primary cultures will be reported at the 2011 ASCO meeting (Nagourney, R., et al Proceedings Amer Soc Clin Oncol. 2011). PARP inhibitors are easily studied and provide interesting signals in the tissues studied. They've also identified synergy with other classes of drugs.

Poly ADP ribose polymerase (PARP) is a nuclear enzyme associated with response to DNA damage. Following single strand DNA breaks, the enzyme attaches a backbone of ADP and ribose that serves to initiate DNA repair. Certain classes of chemotherapeutics, specifically alkylating agents, can induce injury that results in extensive poly ADP ribosylation resulting in the exhaustion of intercellular pools of NAD and ATP ultimately leading to cell death.

Although PARP inhibitors have recently entered the clinical cancer literature mostly relating to the treatment of BRCA+ and triple negative patients, neither PARP nor PARP inhibitors are new to the cancer researcher community. Dr. Robert Nagourney first became interested following a 1988 study by Distelhorst from Case Western Reserve that described a mechanism of cell death that correlated with his work in childhood leukemia.

Nagourney's group has studied small molecule inhibitors of PARP for many years, and more recently, expanded these investigations to include Olaparib and Iniparib. They have explored the biology of PARP inhibitors, alone and in combination, in actual human tumor primary culture microspheroids (microclusters) in breast, ovarian and other cancers. The functional analysis platform explores the biology (real time) how PARP inhibitors enhance the effects of drugs and drug combinations before they are put into the patient.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Ovarian Cancer Discussions

Title Updated Last By Comments
News Longtime cat rescuer falls on hard times (Nov '12) Mar '18 lee 24
News Patsy Ramsey Dies After Battle With Ovarian Cancer (Jun '06) Jan '18 RTIC 34
News Seattle Cancer Care Alliance Opens Prostate Can... (Sep '16) Nov '17 ReneeWilliamson 2
News Walk of Hope set for Sept. 11 to help battle ov... (Sep '11) Jun '17 less hope now 5
News Myriad Genetics Announces an Assay that Identif... (Nov '16) Feb '17 Purplemouse2 8
News Genetic testing lets families affected by breas... (Oct '16) Oct '16 Stephany McDowell 1
News Genetics testing clinic swamped from the 'Angel... (Sep '16) Sep '16 Stephany McDowell 3